Page 169 - Read Online

Elhage et al. Plast Aesthet Res 2020;7:16 I http://dx.doi.org/10.20517/2347-9264.2020.03 Page 9 of 9

laparoscopic repair of complex ventral hernia. Surg Endosc 2018;32:831-9.
20. Bueno-Lledó J, Torregrosa A, Jiménez R, Pastor PG. Preoperative combination of progressive pneumoperitoneum and botulinum toxin type
A in patients with loss of domain hernia. Surg Endosc 2018;32:3599-608.
21. Bueno-Lledó J, Torregrosa-Gallud A. Preoperative botulinum toxin and progressive pneumoperitoneum are useful in the treatment of large
incisional hernias. Am Surg 2019;85:e189-92.
22. Elstner KE, Read JW, Saunders J, Cosman PH, Rodriguez-Acevedo O, et al. Selective muscle botulinum toxin A component paralysis in
complex ventral hernia repair. Hernia 2020;24:287-93.
23. Nielsen M, Bjerg J, Dorfelt A, Jørgensen LN, Jensen KK. Short-term safety of preoperative administration of botulinum toxin A for the
treatment of large ventral hernia with loss of domain. Hernia 2020;24:295-9.
24. Chan DL, Ravindran P, Fan HS, Elstner KE, Jacombs ASW, et al. Minimally invasive Venetian blinds ventral hernia repair with botulinum
toxin chemical component separation. ANZ J Surg 2020;90:67-71.
25. Scaglione F. Conversion ratio between botox®, dysport®, and xeomin® in clinical practice. Toxins (Basel) 2016;8.
26. Booth JH, Garvey PB, Baumann DP, Selber JC, Nguyen AT, et al. Primary fascial closure with mesh reinforcement is superior to bridged
mesh repair for abdominal wall reconstruction. J Am Coll Surg 2013;217:999-1009.
27. Cobb WS, Burns JM, Kercher KW, Matthews BD, James Norton H, et al. Normal intraabdominal pressure in healthy adults. J Surg Res
2005;129:231-5.
28. Ramirez OM, Ruas E, Dellon AL. “Components separation” method for closure of abdominal-wall defects: an anatomic and clinical study.
Plast Reconstr Surg 1990;86:519-26.
29. Novitsky YW, Elliott HL, Orenstein SB, Rosen MJ. Transversus abdominis muscle release: a novel approach to posterior component
separation during complex abdominal wall reconstruction. Am J Surg 2012;204:709-16.
30. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in
humans. Mov Disord 1997;12:89-94.
31. Tomazini Martins R, Elstner KE, Skulina C, Rodriguez-Acevedo O, Read JW, et al. Limitations of electromyography in the assessment of
abdominal wall muscle contractility following botulinum toxin a injection. Front Surg 2019;6:16.
32. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin.
Pharmacology 2015;95:65-9.
33. Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, et al. Botulism in 4 adults following cosmetic injections with an unlicensed,
highly concentrated botulinum preparation. JAMA 2006;296:2476-9.
34. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3:333-5.
35. Herrero BA, Ecklund AE, Spencer Streett C, Ford DF, King JK. Experimental botulism in monkeys-A clinical pathological study. Exp Mol
Pathol 1967;6:84-95.